意大利癌癥發(fā)病情況分析報(bào)告-外文版培訓(xùn)課件2024.7temu

POLITICS

&

SOCIETYCancerinItalyCHAPTER

01OverallincidenceandprevalenceEstimatednumberofnewcancercasesamongmalesinItalyin2023,bytypeofcancerNewcancercasesamongmalesinItaly2023,bytypeofcancerNumberofcancercases15,000

20,00005,00010,00025,00030,00035,00040,00045,000ProstateLung41,10030,000Colorectal26,800Bladder23,700Stomach9,000Liver8,130Non-HodgkinlymphomaKidney8,1007,900Upperaerodigestivetract*Skin(menaloma)Pancreas7,0507,0006,800Leukemia5,300Centralnervoussystem*3,6004Description:In2023,roughly41.1thousandmaleswereestimatedtobenewlydiagnosedwithprostatecancerinItaly.Pertainingtonewdiagnosisamongmales,prostatecancerwastheonewiththehighestincidence,followedbylungandcolorectaltumors,with30thousandand26.8thousandnewcases,respectively.ReadmoreNote(s):Italy;2023;*2022**2020ReadmoreSource(s):AIRTUMonlusEstimatednumberofnewcancercasesamongfemalesinItalyin2023,bytypeofcancerNewcancercasesamongfemalesinItaly2023,bytypeofcancerNumberofcancercases20,000

30,000010,00040,00050,00060,000BreastColorectal55,90023,700Lung14,000UterusThyroidPancreasNon-HodgkinlymphomaBladder10,2008,7008,0006,3006,0006,0006,0005,700StomachOvary*Skin(melanoma)Kidney4,8004,300Leukemia5Description:BreastcancerwasbyfarthemostprevalentcancertypeamongfemalesinItaly,withalmost56thousandestimatednewcases.Colorectalandlungcancerfollowed,withroughly23.7and14thousandindividualsexpectedtosufferfromthesediseases,respectively.ThesetwotypesofcancerwereverycommonamongItalianmenaswell.ReadmoreNote(s):Italy;2023;*2022**2020ReadmoreSource(s):AIRTUMonlusThemostfrequentlydiagnosedcancersamongmalesinItalyin2020and2022*ThemostfrequentlydiagnosedcancersamongmalesinItaly2020and20222020202225%19.8%20%15%10%5%18.5%15%14.1%12%11.4%10.5%4.6%0%ProstateLungColorectalBladderKidney6Description:EveryyearnumerousnewcasesofcancerarediagnosedinItaly.Thefigurepresentedrefertotheshareofspecifictumorsoutofthetotalnumberofcancersdiagnosedamongmalesin2020andin2022,whenthedataisavailable.Accordingtothesource,prostatecancerregisteredthehighestincidenceamongmalesin2022,with19.8percent,followedbylungtumor,with15percent.ReadmoreNote(s):Italy;2020and2022;*Estimatedvalues.Datafor2020aretakenfromInumeridelcancro2020percittadiniepazienti.ReadmoreSource(s):AIOM;AIRTUMonlusThemostfrequentlydiagnosedcancersamongfemalesinItalyin2020and2022*ThemostfrequentlydiagnosedcancersamongfemalesinItaly2020and20222020202235%30.3%30%25%20%15%11.2%10%5%7.3%6%5.4%5.5%4.6%0%BreastColorectalLungThyroidUterus7Description:TherearenumerousnewcasesofcancerthatarediagnosedeveryyearamongtheItalianpopulation.ThisstatisticdepictsthemostfrequentlydiagnosedcancersamongfemalesinItalyin2020and2022,whenthedataisavailable.Thefiguresrefertotheshareofspecifictumorsoutofthetotalnumberofcancersdiagnosedamongfemales.Accordingtothesource,in2020,breastcancerrecordedthehighestincidence,with30.3percent,followedbycolorectaltumors,with11.2percent.

ReadmoreNote(s):Italy;2020and2022;*Estimatedvalues.Datafor2020aretakenfromInumeridelcancro2020percittadiniepazienti.ReadmoreSource(s):AIOM;AIRTUMonlusNumberofmenlivingwithadiagnosisofcancerinItalyasof2020,bytypeofcancerCasesofcancercasesamongmeninItalyasof2020,bytypeofcancerNumberofcancercases0100,000200,000300,000400,000500,000600,000ProstateColon,rectumandanusBladder563,960280,277255,015Colon192,795KidneyurinarytractRectumNon-Hodgkin'slymphomasMelanomas,skinLung97,24986,45482,78080,06977,159TestisStomach63,39550,327LarynxThyroid47,01545,9498Description:Asof2020,almost1.7millionmenwerelivingwithadiagnosisofcancerinItaly.Prostatecancerwasthemostdiagnosedtype,withalmost564thousandmendiagnosedwiththistypeofcancer.ThefigurepresentedshowsthecasesofcanceramongmeninItalyasof2020,bytypeofcancer.ReadmoreNote(s):Italy;2020Source(s):AIOM;AIRTUMonlusNumberofwomenlivingwithadiagnosisofcancerinItalyasof2020,bytypeofcancerCasesofcanceramongwomeninItalyasof2020,bytypeofcancerNumberofcancercases300,000

400,0000100,000200,000500,000600,000700,000800,000900,000BreastColon,rectumandanusThyroid834,154233,245166,914164,924ColonUterus(body)Melanomas,skinNon-Hodgkin'slymphomasRectum122,55389,83173,58461,997BladderUterus,CervixOvary58,60851,13649,80747,15140,657KidneyurinarytractLung9Description:Asof2020,morethan1.9millionwomenwerelivingwithadiagnosisofcancerinItaly.Breastcancerwasthemostdiagnosedtype,withmorethan834thousandwomendiagnosedwiththistypeofcancer.ThefigurepresentedshowsthenumberofcancercasesamongwomeninItalyasof2020,bytypeofcancer.ReadmoreNote(s):Italy;2020Source(s):AIOM;AIRTUMonlusNumberofpeoplelivingwithadiagnosisofcancerinItalyasof2020,bytypeofcancerCasesofcancerinItalyasof2020,bytypeofcancerNumberofcancercases300,000

400,0000100,000200,000500,000600,000700,000800,000900,000BreastProstate834,154563,960Colon,rectumandanusColon513,522357,719Bladder313,624Thyroid212,863169,900156,364Melanomas,skinNon-Hodgkin'slymphomasRectum148,450144,400KidneyurinarytractUterus(body)Lung122,553117,81684,980Leukaemias10Description:Asof2020,morethan3.6millionpeoplewerelivingwithadiagnosisofcancerinItaly.Breastcancerwasthemostdiagnosedtypeamongwomen,withmorethan834thousandwomendiagnosedwiththistypeofcancer,whileprostatecancerwasthemostdiagnosedamongmen.ThefigurepresentedshowsthenumberofcasesofcancerinItalyasof2020,bytypeofcancer.

ReadmoreNote(s):Italy;2020Source(s):AIOM;AIRTUMonlusCHAPTER

02ScreeningShareofwomenundergoingbreastcancerscreeningintheprevioustwoyearsinItalyfrom2008to2022ShareofwomenundergoingbreastcancerscreeninginItaly2008-202276.0%75.0%74.0%73.0%75.2%75.1%74.8%74%73.3%72.5%72%71.9%71.8%72.0%71.0%70.0%69.0%68.0%71.5%70.6%201270.2%200969.9%201069.9%201168.8%2021200820132014201520162017201820192020202212Description:Between2008and2022,theshareofwomenbetween50and69yearsoldundergoingbreastcancerscreeningatleastonceintheprevioustwoyearsinItalyhasbeenalwaysfluctuating,peakingin2017at75.2percent.Asof2022,around71.8percentofwomeninthisagegroupunderwentpreventiveexaminationsforbreastcancer,whereasthepreviousyearrecordedthelowestfigureduringtheconsideredperiod.Theagegroup50-69istheoneforwhichpreventivebreastcancer[...]

ReadmoreNote(s):Italy;2008to2022;50-69yearsSource(s):IstitutoSuperiorediSanitàShareofwomenscreenedforbreastcancerintheprevioustwoyearsinItalybetween2021and2022,byregionShareofwomenscreenedforbreastcancerinItaly2021-2022,byregionShareofwomenundergoingbreastcancerscreening20%

30%

40%

50%0%10%60%70%80%90%100%Friuli-VeneziaGiulia87.8%87.3%Emilia-RomagnaUmbriaLombardy*85.8%84.8%MarcheLiguria84.2%83.7%VenetoTuscany80.8%78.8%AutonomousProvinceofBolzano73.4%72.4%70.8%70.4%69.2%LazioPiedmontItalyAutonomousProvinceofTrento13Description:Between2021and2022,about70.4percentofwomenaged50to69yearsinItalyhadamammogram.Preventivebreastcancerscreeningthroughamammogrameverytwoyearsismostrecommendedforthoseaged50to69years.Between2021and2022,breastcancerscreeningwasmuchmorecommonintheNorthernItalianregions,withratesoftenabove80percent.ReadmoreNote(s):Italy;2021and2022;50-69years;*DataforLombardyrefertotheperiod2016-2019.Releasedaterepresentsthedatefigureswereaccessed.

ReadmoreSource(s):IstitutoSuperiorediSanitàShareofbreastcancerscreeningsinwhichbreastcancerwasdetectedinItalyfrom2014to2022*RateofbreastcancerdetectedafterbreastcancerscreeninginItaly2014-20226%5.1%4.9%5%4%3%2%1%0%4.7%4.6%4.6%4.4%4.4%2014-20152016-20172018201920202021202214Description:Between2014and2022,theshareofbreastcancerscreeningsamongwomeninItalyinwhichbreastcancerwasdetectedfluctuatedslightly.Thelowestratewasrecordedin2018and2019,with4.4percentofscreeningsprovidedeverytwoyearsbytheItalianNationalHealthcareServicetowomenagedbetween50and69yearsdetectingbreastcancer.In2021,therateofdetectedcancerspeakedat5.1percent.ThisstatisticdisplaysthesharebreastcancerscreeningsamongwomeninItaly[...]

ReadmoreNote(s):Italy;2014to2022;50-69years;*AmongwomenwhoacceptedtheinvitationforthebreastcancerscreeningprovidedeverytwoyearsbytheNationalHealthcareService.Datapriorto2019fromearlierpublicationsbythesource.

ReadmoreSource(s):OsservatorioNazionaleScreeningShareofwomenundergoingcervicalcancerscreeninginthepreviousthreeyearsinItalyfrom2008to2022ShareofwomenundergoingcervicalcancerscreeninginItaly2008-202281.5%80.5%81%80.2%80%79.8%79.8%79.5%78.5%77.5%76.5%75.5%74.5%78.9%78.9%78.1%77.8%77.8%77.8%77.6%77.3%77%75.2%20092008201020112012201320142015201620172018201920202021202215Description:Between2008and2022,theshareofwomenagedbetween25and64yearsundergoingcervicalcancerscreeningduringthepreviousthreeyearsinItalyincreasedoverall.In2019,theshareofwomenundertakingtestsabletodiagnosecervicalcancerwasequaltoapproximately81percent,thehighestfigurerecordedduringtheperiodunderconsideration.In2022,however,thispercentagetotaled77.8percent.Theagegroup25to64istheoneforwhichitisrecommendedforwomen[...]

ReadmoreNote(s):Italy;2008to2022;25-64yearsSource(s):IstitutoSuperiorediSanitàShareofwomenscreenedforcervicalcancerinthepreviousthreeyearsinItalybetween2021and2022,byregionShareofwomenscreenedforcervicalcancerinItaly2021-2022,byregionShareofwomenundergoingcervicalcancerscreening20%

30%

40%

50%

60%0%10%70%80%90%100%AutonomousProvinceofBolzano93.2%90.2%87.6%86.4%85%Friuli-VeneziaGiuliaUmbriaAutonomousProvinceofTrentoEmillia-RomagnaVeneto84.9%84.1%83.7%83.4%LiguriaLazioLombardy*MarcheTuscanyPiedmontAostaValley82.4%80.5%78.7%78.3%16Description:Between2021and2022,about77.7percentofwomenaged25to64yearsinItalyunderwentacervicalcancerscreeninginthepreviousthreeyears.Thisstatisticshowsregionalvariationsinthisfigure.Itispossibletonoteaconsiderablegeographicaldifferenceinthisrate:theaverageamongNorthernregionswas84.1percent,whileinSouthernregionsandislands,around69.2percentofwomenunderwentsuchtests.Theagegroup25to64istheoneforwhichitis[...]

ReadmoreNote(s):Italy;2021and2022;25-64years;*DataforLombardyrefertotheperiod2016-2019.Releasedaterepresentsthedatefigureswereaccessed.

ReadmoreSource(s):IstitutoSuperiorediSanitàShareofwomenwhounderwentaPaptestinItalyfrom2009to2021,byagegroupWomenwhounderwentPaptestinItaly2009-2021,byagegroup25-34years35-44years45-54years55-64years42.9%44%43%42.7%42%42.6%42.4%42.2%42%41.7%41.5%42%40%38%36%34%32%30%41.3%41%40.7%40.6%40.4%36.3%40.3%40.2%39.9%39.1%39%38.9%37.6%35.3%36.7%36.3%36.2%36.1%35.8%35%34.3%34.1%34%32.9%31.2%2009-20112012-2014201520162017201820192020202117Description:Between2009and2021,theshareofwomenwhounderwentaPaptestinItalyfluctuated.Thisstatisticbreaksdownthissharebyagegroupofthewomen.Ingeneral,Paptestweremorecommonamongwomenaged45to64years,comparedtoyoungerones.In2021,thenumberofwomenwhounderwentaPaptestreached37.3percentoverall.ReadmoreNote(s):Italy;2009to2021;25-64yearsSource(s):OsservatorioNazionaleScreeningShareofwomenwhounderwenthumanpapillomavirus(HPV)screeninginItalyfrom2018to2022*ShareofwomenwhounderwentHPVscreeninginItaly2018-202260%48.5%50%40%30%20%10%0%45.2%41.3%39.1%37.6%2018201920202021202218Description:Between2018and2022,theshareofwomenwhounderwenthumanpapillomavirus(HPV)screeninginItalyfluctuated.Thelowestratewasrecordedin2020,withonly37.6percentofwomenundergoingHPVscreening,afteracceptingtheinvitationforthescreeningfromtheItalianNHS,likelyduetotheCOVID-19pandemic.ThisstatisticdisplaystheshareofwomenwhounderwentHPVscreeninginItalyfrom2018to2022.ReadmoreNote(s):Italy;2018to2022;25-64years;*Amongwomeninvitedforhumanpapillomavirus(HPV)screeningprovidedeveryfiveyearsin13Italianregions.In2022,around60.4%ofwomenwereinvitedtoundergoHPVscreening.

ReadmoreSource(s):OsservatorioNazionaleScreeningShareofhumanpapillomavirus(HPV)screeningsinwhichHPVwasdetectedinItalyfrom2018to2022*RateofHPVdetectedafterscreeninginItaly2018-202210%9.1%9%8.3%8.1%7.8%7.7%8%7%6%5%4%3%2%1%0%2018201920202021202219Description:Between2018and2022,theshareofhumanpapillomavirus(HPV)screeningsinItalyinwhichHPVwasdetectedincreased.Thehighestratewasrecordedin2021,with9.1percentofscreeningsprovidedeveryfiveyearsbytheItalianNationalHealthcareServicein13oftheItalianregionsresultinginadetection.Thisstatisticdisplaystheshareofhumanpapillomavirus(HPV)screeningsinwhichHPVwasdetectedinItalyfrom2018to2022.ReadmoreNote(s):Italy;2018to2022;25-64years;*Amongwomeninvitedforhumanpapillomavirus(HPV)screeningprovidedeveryfiveyearsin13Italianregions.In2022,around60.4%ofwomenwereinvitedtoundergoHPVscreening.

ReadmoreSource(s):OsservatorioNazionaleScreeningShareofindividualsaged50-69yearsscreenedforcolorectalcancerinItalybetween2021and2022,byregionShareofindividualsscreenedforcolorectalcancerinItalyin2021-2022,byregionShareofindividuals30%

40%0%10%20%50%60%70%80%90%Veneto80.6%Lombardy*Friuli-VeneziaGiulia74.7%72.8%69.5%Emilia-RomagnaAutonomousProvinceofBolzanoAutonomousProvinceofTrento63.4%62.4%62.3%60.2%AostaValleyUmbriaTuscanyMarcheBasilicataLazio58.2%57.8%46%45.8%44.9%Italy20Description:Between2021and2022,about44.9percentofindividualsaged50to69yearsinItalyunderwentcolorectalcancerscreening.Thisstatistichighlightsregionalvariationsinthisfigure.TheregionofApuliahadthelowesttheprevalencerateofcolorectaltestswasaslowas12.3percent.Thisfigureshowstheshareofindividualsaged50-69yearsscreenedforcolorectalcancerinItalybetween2021and2022,byregion.

ReadmoreNote(s):Italy;2021and2022;*DataforLombardyrefertotheyears2016-2019.DataforPiedmontaremissing.Releasedaterepresentsthedatefigureswereaccessed.

ReadmoreSource(s):IstitutoSuperiorediSanitàCHAPTER

03TreatmentandcarePercapitaexpenditureoncancerdrugsinItalyin2022,byregion(ineuros)PercapitaexpenditureoncancerdrugsinItaly2022,byregionExpenditureineuros30

40010205060708090100UmbriaMarcheCampania89.7887.2186.26LiguriaFriuli-VeneziaGiulia82.8282.6582.09Emilia-RomagnaAbruzzo80.5180.32ApuliaBasilicataAutonomousProvinceofBolzano77.174.37LazioTuscanyMolise74.0373.7873.6222Description:In2022,theaverageexpenditureoncancerdrugsinItalywasequalto74.05eurospercapita.Thisfigure,however,variedconsiderablyacrossregions.UmbriaandMarchewerethetworegionsrecordingthehighestexpenditure,withroughly89.8eurosand87.2perinhabitant,respectively.Conversely,inAostaValley,just43.7euroswerespentononcologicaldrugspercapita.ThisstatisticdisplaysthepercapitaexpenditureoncancerdrugsinItalyin2022,byregion.

ReadmoreNote(s):Italy;2022Source(s):AgenziaItalianadelFarmacoExpenditureforoncologydrugsinItalyin2022,bycategory(inmillioneuros)ExpenditureforoncologydrugsinItaly2022,bycategoryExpenditureinmillioneuros02004006008001,000

1,200

1,400

1,600

1,800

2,0001,824.1MonoclonalantibodiesTirosinkinaseinhibitorsCytostaticantineoplastics1,169.4348.3Proteinkinaseinhibitors257.3233.3159.7126.570.3Endocrinetherapy-AromataseInhibitorsEndocrinetherapy-AntiandrogensEndocrinetherapy-HormonesandGnRH(Gonadotropin-releasinghormone)CAR-T23Description:Overthecourseof2022,thetotalexpenditureforoncologydrugsinItalyamountedtoalmost4.4billioneuros.Thisstatisticbreaksdownthisfigurebycategory.Accordingtothedata,thespendingonmonoclonalantibodiesamountedtoapproximately1.8billioneuros,whereastheexpenditurefortyrosinekinaseinhibitorsreachedalmost1.2billioneuros.Thesetwocategorieswerebyfarthetwooncologydrugsonwhichthemostmoneywasspent.

ReadmoreNote(s):Italy;2022Source(s):AgenziaItalianadelFarmacoExpenditureoninnovativecancerdrugsinItalyin2020,byregion(inmillioneuros)ExpenditureoninnovativecancerdrugsinItaly2020,byregionExpenditureinmillioneuros80

1000204060120140160180200220LombardyLazio196.3118CampaniaEmilia-RomagnaVeneto106.798.884.981.478.5TuscanyPiedmontApulia67.866SicilyLiguria36MarcheSardinia29.328.5Friuli-VeneziaGiulia25.524Description:In2020,roughly1.1billioneuroswerespentoninnovativecancerdrugsinItaly.Thisstatisticbreaksdownthisfigurebyregion.Accordingtothedata,inLombardytheexpenditureforinnovativeoncologydrugsamountedtoover196millioneuros.Laziofollowedwithanexpenditureofroughly118millioneuros.ThisstatisticdisplaystheexpenditureoninnovativecancerdrugsinItalyin2020,byregion.ReadmoreNote(s):Italy;2020Source(s):AgenziaItalianadelFarmacoDistributionofexpenditureoncancerdrugsinItalyin2020,bytypeDistributionofexpenditureoncancerdrugsinItaly2020,bytypeOff-patent5.3%Brandname94.7%25Description:In2020,almostalltheexpenditureononcologicaldrugsinItalywasdirectedtowardsbrandnamedrugs.Theyaccounted,infact,for94.7percentofthetotalspending,whereasspendingonoff-patentmedicinesrepresentedtheremaining5.3percent.ThisstatisticdisplaysthedistributionofexpenditureoncancerdrugsinItalyin2020,bytype.ReadmoreNote(s):Italy;2020Source(s):AgenziaItalianadelFarmacoLevelofconsumptionofcancerdrugsinItalyfrom2013to2022(inDDDper1,000inhabitantsperday)ConsumptionofcancerdrugsinItaly2013-2022121010.910.410.210.29.89.59.39.29.28.986420201320142015201620172018201920202021202226Description:Between2013and2022,thelevelofconsumptionofoncologicaldrugsinItalyincreased.Accordingtothedata,thelevelofconsumptionofmedicinestotreatcancerpeakedin2022,reachingavalueof10.9DDD(dailydefineddose)per1,000inhabitantsperday.ThisstatisticdisplaysthelevelofconsumptionofcancerdrugsinItalyfrom2013to2022.ReadmoreNote(s):Italy;2013to2022Source(s):AgenziaItalianadelFarmacoTrendofconsumptionofantineoplasticdrugsinItalyfrom2011to2022(inDDDper1,000inhabitantsperday)ConsumptionofantineoplasticdrugsinItaly2011-202220181618.717.41716.515.414.81413.813.613.213.3141210812.6642020112012201320142015201620172018201920202021202227Description:Between2011and2022,thelevelofconsumptionofantineoplasticdrugsinItalyincreasedsignificantly.Accordingtothedata,infact,theconsumptionofdrugstotreatcancerwasequalto12.6DDD(dailydefineddose)per1,000inhabitantsperdayin2011,whileby2022thisfigureincreasedto18.7DDDper1,000inhabitants.ThisstatisticdisplaystheconsumptionofantineoplasticdruginItalybetween2011and2022.ReadmoreNote(s):Italy;2011to2022Source(s):AgenziaItalianadelFarmacoCHAPTER

04MortalityNumberofdeathsfromcanceramongmeninItalyin2022,bytypeofcancerNumberofdeathsfromcanceramongmeninItalyin2022,bytypeNumberofdeaths10,00005,0004,00015,00020,00025,000LeukaemiasStomachBladder5,7006,400PancreasProstateColorectalLung7,0008,20013,00023,60029/statistics/1325779/number-deaths-from-cancer-among-men-by-type-italyIn2022,lungcancer,followedbycolorectalandprostate,werethetypesofcancercausingthehighestnumberofdeathsamongmeninItaly.ThisgraphshowstheestimatednumberofdeathsfromcanceramongmeninItalyin2022,bytypeofcancer.ReadmoreNote(s):Italy;2022Source(s):AIOM;AIRTUMonlusNumberofdeathsfromcanceramongwomeninItalyin2022,bytypeofcancerNumberofdeathsfromcanceramongwomeninItalyin2022,bytypeNumberofdeaths6,000

8,00002,0001,9004,00010,00012,00014,00016,00018,000BladderLeukaemiasOvary3,2003,6004,200StomachUterus(cervixandbody)Pancreas5,0007,900Colorectal11,200Lung12,100Breast15,50030Description:In2022,breastcancer,followedbylungandcolorectal,werethetypesofcancercausingthehighestnumberofdeathsinItaly.ThisfigureshowstheestimatednumberofdeathsfromcanceramongwomeninItalyin2022,bytypeofcancer.

ReadmoreNote(s):Italy;2022Source(s):AIOM;AIRTUMonlusObservedcancermortalityratesamongmenintheEuropeanUnionandItalyin2015andestimationsfor2021(per100,000inhabitants)Cancermortalityratesamongmen:comparisonbetweenItalyandEUin2015and202120152021*16014012010080139.52130.27125.66113.436040200EuropeanUnionItaly31Description:Accordingtothedata,mortalityratesfromcanceramongmenintheEuropeanUnionandItalyarepredictedtodecreasefrom2015to2021.Moreover,thisstatisticshowsthatcancermortalityratesamongmeninItalyarelowerinrespecttotheEuropeanUnion.ThisfigureshowstheobservedcancermortalityrateamongmenintheEuropeanUnionandItalyin2015andestimationsfor2021(per100,000inhabitants).ReadmoreNote(s):Italy;2015and2021;*EstimatedvalueReadmoreSource(s):AIOM;AIRTUMonlusObservedcancermortalityratesamongwomenintheEuropeanUnionandItalyin2015andestimationsfor2021(per100,000inhabitants)Cancermortalityratesamongwomen:comparisonbetweenItalyandEUin2015and202120152021*908070605040302010084.881.0279.3873.06EuropeanUnionItaly32Description:Accordingtothedata,mortalityratesfromcanceramongwomenintheEuropeanUnionandItalyarepredictedtodecreasebetween2015and2021.Moreover,thisstatisticshowsthatcancermortalityratesamongwomeninItalyarelowerinrespecttotheEuropeanUnion.ThisfigureshowstheobservedcancermortalityrateamongwomenintheEuropeanUnionandItalyin2015andestimationsfor2021(per100,000inhabitants).

ReadmoreNote(s):Italy;2015and2021;*EstimatedvalueReadmoreSource(s):AIOM;AIRTUMonlusCancermortalityrateinItalyfrom2006to2020(per10,000inhabitants)CancermortalityrateinItaly2006-202029.028.027.026.025.024.023.028.728.728.328.127.627.32726.225.825.625.32524.724.323.920062007200820092010201120122013201420152016201720182019202033Description:Accordingtothedata,thenumberofindividualswhodiedfromatumorinItalydecreasedconstantlybetween2006and2020.Indeed,therateofdeathsduetocanceramongItaliansdroppedfrom28.7deathsper10,000inhabitantsin2006to23.9in2020.Moreover,inItaly,thecancermortalityratesamongwomenandmenarelowerthantheonesobservedintheEuropeanUnion.

ReadmoreNote(s):Italy;2006to2020Source(s):IstatCancermortalityrateamongmalesinItalyfrom2006to2020(per10,000inhabitants)CancermortalityrateamongmalesinItaly2006-20204540.339.339.338.840353025201510538.137.436.935.634.934.233.833.332.631.931.1020062007200820092010201120122013201420152016201720182019202034Description:Between2006and2020,thecancermortalityrateamongmalesinItalydecreasedconsiderably.Accordingtothedata,indeed,ifin2006thenumberofmalesdyingfromcancerwasjustover40individualsoutof10,000inhabitants,by2020thisfigureamountedto31.1individuals.ThisstatisticshowsthecancermortalityrateamongmalesinItalyfrom2006to2020.ReadmoreNote(s):Italy;2006to2020Source(s):IstatCancermortalityrateamongfemalesinItalyfrom2006to2020(per10,000inhabitants)CancermortalityrateamongfemalesinItaly2006-20202521.221212120.620.520.319.919.619.719.419.419.2201510518.918.9020062007200820092010201120122013201420152016201720182019202035Description:Between2006and2020,thecancermortalityrateamongfemalesinItalydecreased.Accordingtothedata,in2020,18.9femalesdiedofcanceroutof10,000femalesinthecountry,whilein2006themortalityratewasequalto21.ThisstatisticdisplaysthecancermortalityrateamongfemalesinItalyfrom2006to2020.ReadmoreNote(s):Italy;2006to2020Source(s):IstatCHAPTER

05CancerriskfactorsShareofmaleindividualsconsumingalcoholicbeveragesinItalyin2021,bytypeofbeverageMalealcoholconsumptioninItaly2021,bytypeofbeverage90%80%77.2%70%60%50%40%30%20%10%0%65.7%64%56.6%WineBeerCocktails,Spirits,HardliquorsTotal37Description:Overthecourseof2021,over77.2percentofthemalepopulationover11yearsofageinItalyconsumedsomekindofalcoholicbeverageatleastonce.Breakingdownthisfigurebytypeofbeverage,wineprovedtobethemostpopulardrink,with65.7percentofmenconsumingwineatleastonceovertheprevious12months,whiletheshareofmaleindividualswhodrank